Literature DB >> 29633130

Clinician Referrals for Non-opioid Pain Care Following Discontinuation of Long-term Opioid Therapy Differ Based on Reasons for Discontinuation.

Travis I Lovejoy1,2,3, Benjamin J Morasco4,5, Michael I Demidenko4, Thomas H A Meath4,6, Steven K Dobscha4,5.   

Abstract

BACKGROUND: Little is known about pain care offered to patients discontinued from long-term opioid therapy (LTOT) by their prescriber due to aberrant behaviors versus other reasons.
OBJECTIVE: This study aimed to compare rates of non-opioid analgesic pharmacotherapy initiation and clinician referrals for non-pharmacologic pain treatment, complementary and integrative pain therapies, and specialty mental health and substance use disorder treatment between patients discontinued from opioid therapy due to aberrant behaviors versus other reasons.
DESIGN: The design included retrospective manual electronic health record review and administrative data abstraction. PARTICIPANTS: Patients were sampled from a national cohort of US Department of Veterans Affairs patients prescribed continuous opioid therapy in 2011 who subsequently discontinued opioid therapy in 2012. The study sample comprised 509 patients discontinued from LTOT by opioid-prescribing clinicians. MAIN MEASURES: The primary independent variable was reason for discontinuation of LTOT (aberrant behaviors versus other reasons). Pain care dichotomous outcomes included clinician use of an opioid taper; initiating new non-opioid analgesic pharmacotherapy; and referrals for non-pharmacologic pain treatment, complementary and integrative pain therapies, and specialty mental health and substance use disorder treatment. KEY
RESULTS: We observed low rates of opioid taper (15% of patients), initiations of new or modifications of existing non-opioid analgesic pharmacotherapy (45% of patients), and clinician referrals for non-pharmacologic pain treatment (58% of patients) and complementary and integrative therapies (25% of patients). Patients discontinued due to aberrant behaviors, relative to patients discontinued for other reasons, were more likely to receive opioid tapers (adjusted OR = 5.60, 95% CI = 2.10-14.93), receive new non-opioid analgesic medications or dose changes to an existing non-opioid analgesic medications (adjusted OR = 2.61, 95% CI = 1.59-4.29), or be referred for specialty substance use disorder treatment (adjusted OR = 7.39, 95% CI = 3.76-14.53).
CONCLUSIONS: These findings highlight the variability in referral rates for different types of non-opioid pain treatments and challenges accessing specific types of pain care.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29633130      PMCID: PMC5902348          DOI: 10.1007/s11606-018-4329-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  16 in total

1.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

2.  Utilization of Mental Health Services by Veterans Living in Rural Areas.

Authors:  Judith Teich; Mir M Ali; Sean Lynch; Ryan Mutter
Journal:  J Rural Health       Date:  2016-10-04       Impact factor: 4.333

3.  Adherence to clinical guidelines for opioid therapy for chronic pain in patients with substance use disorder.

Authors:  Benjamin J Morasco; Jonathan P Duckart; Steven K Dobscha
Journal:  J Gen Intern Med       Date:  2011-05-12       Impact factor: 5.128

4.  National study of discontinuation of long-term opioid therapy among veterans.

Authors:  Erik R Vanderlip; Mark D Sullivan; Mark J Edlund; Bradley C Martin; John Fortney; Mark Austen; James S Williams; Teresa Hudson
Journal:  Pain       Date:  2014-09-30       Impact factor: 6.961

5.  Association between substance use disorder status and pain-related function following 12 months of treatment in primary care patients with musculoskeletal pain.

Authors:  Benjamin J Morasco; Kathryn Corson; Dennis C Turk; Steven K Dobscha
Journal:  J Pain       Date:  2010-09-20       Impact factor: 5.820

6.  Trends in prevalent and incident opioid receipt: an observational study in Veterans Health Administration 2004-2012.

Authors:  H J Mosher; E E Krebs; M Carrel; P J Kaboli; M W Vander Weg; B C Lund
Journal:  J Gen Intern Med       Date:  2014-12-18       Impact factor: 5.128

7.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

8.  National dissemination of cognitive-behavioral therapy for chronic pain in veterans: therapist and patient-level outcomes.

Authors:  Michael O Stewart; Bradley E Karlin; Jennifer L Murphy; Susan D Raffa; Sarah A Miller; John McKellar; Robert D Kerns
Journal:  Clin J Pain       Date:  2015-08       Impact factor: 3.442

9.  Secular trends in opioid prescribing in the USA.

Authors:  Edmund J Pezalla; David Rosen; Jennifer G Erensen; J David Haddox; Tracy J Mayne
Journal:  J Pain Res       Date:  2017-02-14       Impact factor: 3.133

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more
  2 in total

1.  Role of Rehabilitation in Opioid Tapering: A Scoping Review.

Authors:  Miranda Wiens; Devon Jarrett; Alissa Settimi; Courtney White; Zachary Hollingham; Tara Packham
Journal:  Physiother Can       Date:  2021-06-07       Impact factor: 1.037

Review 2.  Best Practices, Research Gaps, and Future Priorities to Support Tapering Patients on Long-Term Opioid Therapy for Chronic Non-Cancer Pain in Outpatient Settings.

Authors:  Robert Chuck Rich; Roger Chou; Edward R Mariano; Anna Legreid Dopp; Rebecca Sullenger; Helen Burstin
Journal:  NAM Perspect       Date:  2020-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.